Clevor (ropinirole)

Clevor is an FDA-approved veterinary ophthalmic solution containing ropinirole, a dopamine D2 and D3 receptor agonist that induces vomiting in dogs when administered as eye drops. This innovative formulation represents a significant advancement in emergency veterinary medicine, providing a reliable, easy-to-administer emetic for rapid gastric decontamination following toxic substance ingestion. Approved by the FDA in 2020, Clevor offers veterinary professionals a modern alternative to traditional injectable emetics with a unique administration route that simplifies the treatment process.

The mechanism of action of Clevor involves stimulation of dopamine receptors in the chemoreceptor trigger zone (CTZ) located in the area postrema of the brain. When absorbed through the highly vascular conjunctival membranes of the eye, ropinirole reaches the systemic circulation and crosses to the CTZ, triggering the vomiting reflex. This central mechanism produces reliable emesis independent of gastric contents or local irritation, making Clevor effective across a wide range of poisoning scenarios. The onset of emesis typically occurs within fifteen to thirty minutes of administration.

Clevor is supplied as a 30 mg/mL ophthalmic solution in a multi-dose bottle with a metered dropper designed to deliver consistent drop volumes. Administration involves placing drops into one or both eyes based on the dog's body weight, following the manufacturer's dosing guide. The ophthalmic route eliminates the need for injection, simplifying administration and reducing patient restraint requirements. The medication provides predictable emesis in clinical trials, with high success rates across various patient sizes and clinical situations.

As with all emetic agents, Clevor should only be used when induction of vomiting is appropriate and safe. The decision to induce emesis must be made by a veterinary professional who can evaluate the specific toxin involved, time since ingestion, patient clinical status, and any contraindications. Clevor is not appropriate for all poisoning situations, and certain ingested substances or patient conditions preclude safe use of any emetic. When properly indicated and administered, Clevor provides an effective tool for emergency decontamination that can prevent serious toxicity and save lives.

The primary indication for Clevor in dogs is the induction of vomiting following recent ingestion of toxic substances when emesis is deemed appropriate and safe by a veterinary professional. This medication serves as a first-line intervention in emergency toxicology cases where removing the ingested material from the stomach can prevent or reduce systemic toxicity. Common poisoning scenarios appropriate for Clevor treatment include ingestion of chocolate, xylitol-containing products, grapes and raisins, certain human medications, rodenticides, and various household chemicals.

Clevor proves particularly valuable when rapid emesis induction is needed but injection-related challenges complicate traditional emetic administration. Dogs that are difficult to restrain, those with limited venous access, or patients where injection causes excessive stress may benefit from the less invasive ophthalmic route. The predictable drop-based dosing system also simplifies administration compared to injection-based dosing calculations, though veterinary guidance remains essential for appropriate use.

The medication is most effective when administered within one to two hours of toxin ingestion, before the ingested substance has passed from the stomach into the small intestine where it can no longer be retrieved through vomiting. Earlier treatment generally produces better outcomes, as less time allows for absorption of the toxic material. However, the decision to induce vomiting must balance the potential benefit against any risks specific to the ingested substance and patient status.

Clevor may be used for recently ingested foreign bodies in appropriate situations where the object is suitable for removal through emesis. Soft, small, non-sharp objects ingested very recently may be candidates for emetic retrieval, though this decision requires careful professional judgment. Sharp objects, large items, or materials that could cause additional damage during regurgitation should not be addressed with induced vomiting.

Veterinary professionals select Clevor when its specific advantages align with patient needs and clinical circumstances. The medication's FDA veterinary approval, validated efficacy data, predictable performance, and ease of administration make it an attractive option for many emergency decontamination situations. The choice between Clevor and alternative emetics such as apomorphine depends on availability, patient factors, practitioner preference, and specific clinical scenarios.

Clevor administration follows a weight-based dosing protocol using the manufacturer-supplied dropper that delivers standardized drop volumes. The dosing guide specifies the number of drops to administer based on the dog's body weight, eliminating complex dose calculations while ensuring appropriate medication delivery. Veterinary professionals should confirm accurate patient weight before administration and follow the current prescribing information for specific dosing recommendations.

The standard administration technique involves placing the prescribed number of drops into the conjunctival sac of one or both eyes. For smaller doses requiring few drops, administration to a single eye is typically sufficient. Larger doses may be divided between both eyes to improve patient comfort and absorption consistency. The drops should contact the conjunctival membrane rather than the corneal surface when possible, though the medication is absorbed effectively from either location. Dogs may be positioned standing, sitting, or in lateral recumbency for administration.

Onset of emesis typically occurs within fifteen to thirty minutes following Clevor administration, with most dogs beginning to vomit by the twenty-minute mark. Multiple vomiting episodes usually follow the initial emesis, providing thorough gastric evacuation. The duration of the emetic effect generally spans thirty to sixty minutes, after which additional vomiting becomes unlikely. If no vomiting occurs within thirty minutes, veterinary professionals must reassess the situation and consider alternative decontamination approaches.

Unlike conjunctival apomorphine tablets, Clevor drops cannot be physically removed to stop the emetic effect once administered. This characteristic requires confidence that emesis is appropriate before administration, as the effect cannot be rapidly reversed. The medication is absorbed relatively quickly through the conjunctival membranes, initiating the emetic cascade before any intervention could halt the process. This differs from tablet-based conjunctival administration where tablet removal can terminate drug absorption.

A second dose of Clevor may be considered if the initial administration fails to produce adequate emesis, following the manufacturer's guidance for repeat dosing. However, repeated dosing increases the risk of side effects and should only be undertaken when the clinical benefit clearly justifies the additional risk. If a second dose also fails to produce vomiting, alternative approaches such as gastric lavage may be necessary depending on the clinical urgency.

Post-emesis management following successful Clevor administration typically includes monitoring for complications, activated charcoal administration when appropriate for the ingested substance, and supportive care as indicated. The specific follow-up protocol depends on the toxin involved, the estimated amount ingested, and the completeness of gastric evacuation achieved. Veterinary guidance ensures appropriate ongoing management for each patient's individual circumstances.

Clevor is generally well-tolerated in dogs when administered according to prescribing guidelines, with most side effects being predictable consequences of its pharmacological action. Understanding the expected side effect profile helps veterinary professionals provide appropriate patient monitoring and recognize when intervention may be needed. Clinical trials demonstrated acceptable safety across various patient populations.

The most commonly observed side effects include transient ocular effects at the administration site. Mild conjunctival redness, eye discharge, and squinting may occur following drop administration. These effects typically resolve without treatment within a few hours of administration. Occasional patients may show more pronounced ocular irritation, though serious eye complications are uncommon. Pre-existing ocular conditions may influence the degree of local reaction.

Systemic side effects related to dopamine receptor stimulation include lethargy and sedation in some patients. The central nervous system effects of ropinirole can produce drowsiness that persists for variable periods after administration. Most dogs recover normal alertness within two to four hours following treatment. Some patients may show mild tremors or restlessness during the initial period following administration, particularly before vomiting begins when nausea may be present.

Cardiovascular effects observed in clinical use include changes in heart rate and blood pressure. Some dogs experience mild to moderate decreases in blood pressure following Clevor administration. Bradycardia (slow heart rate) can occur and typically resolves spontaneously as the drug effects wane. These cardiovascular changes are usually clinically insignificant in healthy patients but may warrant closer monitoring in patients with pre-existing cardiac conditions or hemodynamic instability.

Serious side effects are uncommon but may include prolonged vomiting, severe sedation, or pronounced cardiovascular effects in sensitive individuals. Aspiration pneumonia represents a potential complication of any induced vomiting episode if the patient cannot adequately protect their airway. Proper patient selection and monitoring minimize these risks. Dogs showing unexpected or severe reactions should receive appropriate supportive care.

Rare adverse events reported during clinical trials and post-marketing surveillance inform ongoing safety monitoring. As with any medication, individual patients may show idiosyncratic reactions not predicted by the general population response. Veterinary professionals should report unexpected adverse events to support ongoing safety evaluation. The overall safety profile of Clevor supports its use as directed for appropriate candidates requiring emergency emesis induction.

Clevor shares the general contraindications applicable to all emetic agents, plus specific considerations related to its formulation and route of administration. Recognizing these contraindications helps veterinary professionals select appropriate candidates for treatment and avoid potentially harmful use in patients where induced vomiting poses unacceptable risks.

Ingestion of caustic or corrosive substances represents an absolute contraindication to Clevor and all emetic use. Strong acids, alkalis, and similar corrosive materials cause chemical burns to the esophagus and stomach, and inducing vomiting forces these substances to pass through the esophagus again, dramatically worsening the injury. Products in this category include drain cleaners, oven cleaners, battery acid, and certain industrial chemicals. Even suspected exposure to corrosive substances should preclude emetic use.

Petroleum distillates and volatile hydrocarbons contraindicate emesis induction due to aspiration risk. Products containing gasoline, kerosene, lamp oil, paint thinners, and similar volatile substances can cause severe chemical pneumonia if aspirated into the lungs during vomiting. The lung damage from aspiration often poses greater risk than the systemic toxicity from GI absorption, making conservative management preferable in these cases.

Altered consciousness represents a critical contraindication because patients with decreased alertness cannot protect their airways during vomiting. Dogs showing signs of sedation, stupor, coma, or seizure activity should not receive Clevor or other emetics. Similarly, patients who have ingested substances likely to cause rapid neurological deterioration may become unable to protect their airway during the time between administration and onset of emesis.

Ocular contraindications specific to Clevor include known hypersensitivity to ropinirole or the formulation components, severe ocular disease or recent eye surgery that could be worsened by drop administration, and conditions affecting conjunctival drug absorption. Dogs with severe conjunctivitis, corneal ulceration, or other significant eye pathology may not be appropriate candidates for Clevor, though alternative emetics could be considered.

Additional contraindications include patients with known hypersensitivity to dopamine agonists, severe cardiovascular instability where the hemodynamic effects of ropinirole could be dangerous, and situations where significant time has elapsed since toxin ingestion such that vomiting would provide minimal benefit. Sharp or pointed foreign bodies should not be addressed with any emetic due to perforation risk during regurgitation. Veterinary judgment integrates all patient factors to determine whether Clevor use is appropriate.

Understanding potential drug interactions with Clevor helps veterinary professionals anticipate modified responses and complications when patients have received other medications. The interaction profile relates primarily to ropinirole's dopaminergic mechanism and its systemic effects following absorption. While emergency administration often proceeds despite potential interactions due to clinical urgency, awareness enables appropriate monitoring and supportive care.

Antiemetic medications can antagonize Clevor's emetic effect, potentially reducing or preventing vomiting. Dopamine receptor antagonists such as metoclopramide, chlorpromazine, and prochlorperazine directly block the receptors that Clevor stimulates, which may render the medication ineffective. Dogs that have recently received antiemetic therapy may show reduced or absent response to Clevor. This interaction should be considered when evaluating patients who fail to vomit following apparently adequate Clevor administration.

Central nervous system depressants may potentiate the sedative effects observed with Clevor. Opioid analgesics, benzodiazepines, phenothiazine tranquilizers, and other sedating medications could produce additive CNS depression when combined with ropinirole's effects. Patients receiving such medications may show more pronounced or prolonged sedation following Clevor administration and may require enhanced monitoring for respiratory depression.

Cardiovascular medications may interact with Clevor's hemodynamic effects. Beta-blockers could potentiate the bradycardic effects sometimes observed with ropinirole. Antihypertensive medications may add to blood pressure-lowering effects. Patients receiving cardiac medications should be monitored appropriately for hemodynamic changes following Clevor administration, though emergency decontamination typically takes priority over interaction concerns.

The presence of certain toxins in the patient's system creates complex interaction scenarios. Substances with CNS depressant properties may enhance sedation and impair airway protection. Toxins affecting cardiovascular function may interact unpredictably with ropinirole's effects. These considerations factor into the overall risk-benefit assessment for emesis induction rather than representing absolute contraindications.

Dopamine agonist medications used for other purposes could produce additive dopaminergic effects if a patient were concurrently receiving such therapy, though this scenario is uncommon in veterinary patients. The pharmacological similarity between ropinirole and other dopamine agonists suggests potential for enhanced or prolonged effects. Complete medication history, when available, informs risk assessment for Clevor administration.

Safe and effective Clevor use requires attention to numerous precautions that optimize patient outcomes while minimizing complication risk. These considerations span patient selection, administration technique, monitoring requirements, and post-procedure management. Establishing protocols that incorporate these precautions supports consistent, high-quality emergency care.

Patient positioning during and after Clevor administration affects aspiration risk. Dogs should be monitored in positions that promote expulsion of vomited material rather than aspiration, typically with the head positioned lower than or level with the body during active vomiting. Heavily sedated patients require particular attention to airway protection. Veterinary staff should remain with the patient during the emesis period rather than leaving the animal unattended.

Time since ingestion critically affects the appropriateness and likely benefit of Clevor administration. Emesis is most effective within one to two hours of toxin ingestion, before significant gastric emptying has occurred. Beyond four hours post-ingestion, the likelihood of retrieving meaningful stomach contents decreases substantially for most substances. The decision to proceed with emesis induction must weigh potential benefit against the procedure's inherent risks.

Complete patient assessment should precede Clevor administration whenever possible. Factors to evaluate include cardiovascular stability, neurological status, respiratory function, hydration status, and any contraindications. Emergency situations may require proceeding with limited assessment when the urgency of decontamination outweighs the value of comprehensive evaluation, but baseline awareness of patient status supports appropriate monitoring and intervention.

Ocular health assessment is prudent before ophthalmic Clevor administration. Dogs with obvious eye pathology such as severe conjunctivitis, corneal injury, or recent ophthalmic surgery may not be optimal candidates for this administration route. Alternative emetics should be considered for patients with significant pre-existing eye conditions that could be worsened by drop administration.

Special populations requiring modified approaches include pediatric patients, geriatric patients, patients with cardiac disease, and those with hepatic impairment that might affect drug metabolism. While specific dose modifications are not established, enhanced monitoring and readiness for supportive intervention are prudent in these groups. Brachycephalic breeds with compromised airways warrant particular attention during any vomiting episode due to their elevated aspiration risk.

Proper storage of Clevor maintains medication stability and ensures reliable potency when needed for emergency situations. The ophthalmic solution should be stored at controlled room temperature, typically between 20 and 25 degrees Celsius (68 to 77 degrees Fahrenheit), with excursions permitted between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit). The medication should be protected from light by storage in its original carton when not in use.

The multi-dose bottle requires attention to sterility and stability after initial opening. Once opened, the product should be used within the timeframe specified by the manufacturer, typically 28 days, after which remaining medication should be discarded regardless of apparent volume remaining. Recording the opening date on the bottle or carton supports compliance with beyond-use dating. Contamination of the dropper tip should be avoided by preventing contact with any surface including the patient's eye when possible.

Emergency medication accessibility means Clevor should be stored in locations where poisoning emergencies are likely to be managed. Treatment areas, emergency supply stations, and on-call kits should include Clevor when it is part of the practice's emergency protocol. Clear organization and labeling facilitate rapid retrieval during urgent situations. Regular inventory checks ensure adequate unexpired stock is maintained.

The bottle dropper mechanism should be kept clean and functional. Clogged or damaged droppers may affect dose accuracy and should prompt replacement of the product. The dropper should be tested periodically to confirm proper function before emergency need arises. Staff training on proper administration technique includes dropper handling and drop placement.

Safe handling protects both patients and personnel. While Clevor is an ophthalmic solution rather than an injectable medication, good practices include hand washing after handling and avoiding self-administration of drops that could cause unintended effects. Accidental human exposure should be reported to medical providers if symptoms develop. Unused medication disposal follows appropriate pharmaceutical waste protocols rather than standard trash or drain disposal.

Stock rotation ensures older products are used before newer inventory, minimizing waste from expiration. Monitoring expiration dates and reordering before stock expires maintains emergency readiness. Temperature excursion events should prompt evaluation of product integrity, with replacement if storage conditions may have compromised stability.

Clevor has been studied and approved for use across diverse dog breeds, with no breed-specific contraindications identified in prescribing information. However, certain breed characteristics influence monitoring priorities and may affect individual patient responses. Understanding these considerations supports optimized care for patients of all breeds requiring emergency emesis induction.

Brachycephalic breeds present special considerations for any emesis-inducing procedure due to their compromised upper airway anatomy. Bulldogs, French Bulldogs, Pugs, Boston Terriers, Pekingese, and similar short-nosed breeds have anatomical features that increase aspiration risk during vomiting. These patients require particularly careful positioning and monitoring during and after Clevor administration. Staff should be prepared to provide airway support if respiratory compromise develops. The ocular conformation of some brachycephalic breeds, including their prominent eyes, may actually facilitate Clevor drop administration.

The MDR1 gene mutation common in herding breeds affects sensitivity to certain medications but has not been specifically implicated in altered Clevor response. Breeds commonly carrying this mutation include Collies, Australian Shepherds, Shetland Sheepdogs, Border Collies, Old English Sheepdogs, and mixed breeds with herding heritage. While vigilance is appropriate when administering any medication to MDR1-affected breeds, ropinirole is not identified as an MDR1-affected substrate in current literature. Standard dosing and monitoring protocols apply to these breeds pending further data.

Size variations across breeds affect dosing and practical administration considerations. Giant breeds such as Great Danes, Mastiffs, and Irish Wolfhounds require larger numbers of drops according to the weight-based dosing guide, which may extend administration time. Toy and miniature breeds including Chihuahuas, Yorkshire Terriers, and Maltese require fewer drops, making accurate counting important to avoid under- or overdosing. The standardized dropper helps ensure consistent drop volumes across the dosing range.

Age-related considerations intersect with breed characteristics in clinical decision-making. Pediatric patients of any breed have immature metabolic systems that may affect drug handling. Geriatric patients may show enhanced sensitivity to dopaminergic effects or have concurrent conditions affecting tolerance. Giant breeds reach geriatric status earlier than small breeds, so a seven-year-old Great Dane may warrant geriatric precautions while a seven-year-old Chihuahua would not. Individual patient assessment guides monitoring intensity and supportive care readiness regardless of breed.

Several other medications serve emetic functions in veterinary medicine, providing alternatives to Clevor when specific circumstances warrant different approaches. Understanding the range of available options helps veterinary professionals select optimal treatments based on drug availability, patient factors, and clinical scenarios. Each emetic agent has distinct characteristics affecting its suitability for particular situations.

Apomorphine represents the traditional veterinary emetic against which Clevor is often compared. This dopamine agonist can be administered by injection or conjunctival tablet placement, with both routes providing reliable emesis in most dogs. Apomorphine has a long track record in veterinary practice and remains widely available. The conjunctival tablet route offers similar ease of administration to Clevor eye drops, while the injectable option provides an alternative when ophthalmic administration is not suitable. Apomorphine tablet removal can reverse ongoing drug effects, unlike Clevor drops which cannot be retrieved.

Hydrogen peroxide (3% solution) represents the most commonly available home emetic, though its use is generally discouraged without veterinary guidance. When administered orally at appropriate doses, hydrogen peroxide causes local gastric irritation triggering the vomiting reflex. This mechanism differs from the central dopamine receptor stimulation used by Clevor and apomorphine. Hydrogen peroxide produces less reliable emesis than Clevor, with success rates varying considerably. Gastric irritation and potential ulceration represent concerns with this agent, making professional emetics preferred when available.

Activated charcoal serves complementary rather than alternative functions in poisoning management. Following successful emesis with Clevor or other agents, activated charcoal administration binds toxin remaining in the gastrointestinal tract, reducing ongoing absorption. Some toxins are poorly bound by charcoal, and not all poisoning situations warrant its use. Charcoal should not be given before emesis as it interferes with assessment of vomited stomach contents.

Gastric lavage represents an alternative decontamination approach when emesis is contraindicated, unsuccessful, or insufficient. This procedure requires general anesthesia and specialized equipment, limiting its availability to fully equipped veterinary facilities. Lavage may be indicated when corrosive substances contraindicate emesis or when very recent ingestion of life-threatening quantities warrants aggressive decontamination beyond what emesis alone can achieve. The decision between emesis and lavage involves complex clinical judgment based on the specific situation. Clevor and other emetics serve as first-line approaches in most appropriate cases, with lavage reserved for specific circumstances.